Background The SNAP (Smoking and Nicotine in Pregnancy) trial compared nicotine replacement therapy (NRT) patches with placebo in pregnant smokers; although NRT doubled cessation rates in the fi rst 4 weeks, by delivery no diff erences in maternal smoking or birth outcomes were noted. As a result, NRT used in standard doses during pregnancy is considered ineff ective for smoking cessation. Subsequent eff ects of NRT on the children of treated mothers are unknown because no trials have investigated the eff ect of gestational NRT use beyond birth. To assess whether NRT use in pregnancy might cause harm to infants, we aimed to compare eff ects of NRT and placebo on infant development 2 years after delivery.
Introduction
Smoking in pregnancy is the biggest preventable cause of death and illness in women and infants and is associated with adverse pregnancy and birth outcomes. 1, 2 Despite being an international public health problem, and although the prevalence of smoking in pregnancy is generally falling in high-income countries, [3] [4] [5] [6] rates are rising in many low-income settings 7 and are expected to substantially increase the future attributable global disease burden. 8 Additionally, rates of smoking are higher, and declines have often been smaller, in mothers who are younger or have lower socioeconomic status. [3] [4] [5] 9 Smoking in pregnancy might aff ect infant development and is associated with behavioural problems, attention defi cit disorder, 10, 11 and reduced academic attainment in children. 10 Nicotine replacement therapy (NRT) helps nonpregnant smokers to stop, 12 but although evidence suggests that it might help pregnant smokers to achieve short-term abstinence, 13 compliance with NRT is generally poor and by delivery there is no longer any evidence for eff ectiveness.
14 Previously, we reported smoking cessation outcomes from a large trial investigating the effi cacy of 15 mg/16 h NRT patches used in pregnancy (the Smoking and Nicotine in Pregnancy [SNAP] trial). 13 We reported that NRT had no eff ect on validated abstinence from smoking at delivery, although validated cessation rates at 1 month after randomisation were twice as high in the NRT group; no safety issues were identifi ed, with adverse pregnancy and birth outcomes similar in the two groups. 13 To our knowledge, no trials have investigated the eff ect of NRT on outcomes for children beyond delivery; thus we designed our study also to assess this. Nicotine is potentially fetotoxic. 15 One theory is that nicotine from either smoking or NRT might stimulate CNS nicotinic receptors at inappropriate times during development and, consistent with this, nicotine given to pregnant rats has a negative eff ect on neurogenesis and synaptogenesis in the fetal CNS. 15 Therefore, observed associations between parental smoking and adverse infant develop ment could be plausible, 10, 11 and might be caused by nicotine inhalation from cigarette smoke. As a result, NRT might benefi t the fetus and child by reducing exposure to smoking at crucial times for embryogenesis and infant neural development, but it may also cause harm through the negative eff ects of direct activation of nicotinic cholinergic receptors in the developing CNS. To assess whether NRT patches use by pregnant smokers who are trying to quit might be harmful, we compared health outcomes at 2 years between infants born in placebo group and active group from the SNAP trial.
Methods

Study design and participants
SNAP was a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial that recruited 1050 pregnant smokers from seven hospital antenatal clinics in England between May 1, 2007, and Feb 26, 2010 ; we have previously reported the full methods and outcomes at delivery. 13 Briefl y, participants were aged 16-45 years, 12-24 weeks' gestation, smoked 10 or more cigarettes daily before pregnancy, and were smoking fi ve or more cigarettes per day at trial enrolment, with an exhaled carbon monoxide (CO) reading of at least 8 ppm. Research midwives obtained written consent, collected baseline data, and delivered behavioural cessation support to all participants. The research midwives then entered eligibility criteria onto a secure online database.
The study was approved by Oxfordshire Research Ethics Committee A, and all participants gave written informed consent, including access to medical records for maintaining contact and for following up theirs and their child's health status.
Randomisation and masking
Participants were randomly assigned (1:1) to receive up to 8-weeks treatment with NRT (15 mg/16 h transdermal patches) or identically packaged and visually matched placebo patches (all patches manufactured by and purchased at market rate from United Pharmaceuticals, Amman, Jordan), issued as two 4-week supplies (521 for NRT group, 529 for placebo group). Participants were instructed to start using these patches on their quit date, to remove them at night, and to only use the patches if they were not smoking. Participants were issued with the second 4-week supply of patches if they reported not smoking one month after their quit date, and this was validated with a CO reading less than 8 ppm.
Randomisation was stratifi ed by site, and used a computer-generated pseudorandom code with permuted blocks of randomly varying size, created by Nottingham Clinical Trials Unit. All participants, site pharmacists, and research staff were masked to treatment allocation. Additionally, during the 2-year follow-up period after ascertainment of primary outcome at delivery, participants, health-care professionals, and all staff involved in collecting, entering, and classifying follow-up data remained masked. Data cleaning and preparatory work were done masked to treatment allocation, and all analyses at delivery were done masked to study group allocation, with codes broken after these were completed. However, analysis of the follow-up data was not possible in a completely blind manner, because the unblinded data from the primary trial was already available. We did not evaluate the success of masking for participants or research staff .
Procedures
Participants' smoking status was assessed 1 month after randomisation and at delivery, with self-reported nonsmoking status validated by CO concentration, salivary cotinine (cotinine is the primary metabolite of nicotine) concentration, or both; those participants who had CO validated cessation at 1 month (<8 ppm) could receive a further 4-week supply of patches. To estimate treatment adherence, participants were asked how many study patches they had used at 1 month, 2 months (if issued with a second 4-week supply), and delivery, and if they had used any non-trial NRT.
Safety was assessed by collection of adverse pregnancy and birth outcomes from participants and medical notes.
Of 1050 pregnancies, 1034 known live births (1010 singletons, 24 twins), fi ve miscarriages, seven stillbirths, one termination, one missed abortion, and 14 pregnancies with unknown birth outcomes were noted. 13 Participants with known live infants were posted questionnaires at 6, 12, and 24 months after childbirth.
For more details on how items were mapped, see the Statistical Analysis Plan at http://eprints. nottingham.ac.uk/3283/ We did not send questionnaires where participants had withdrawn consent, when birth outcomes were unknown, or infants who had died either during pregnancy or after birth. At each timepoint, we sent one postal reminder and attempted telephone completion if necessary. To maintain contact, we sent greetings cards after childbirth, at Christmas, and on infant's birthdays, including postcards to inform us of address changes. We incentivised the return of completed questionnaires with a cotton bag at 1 year and a £5 shopping voucher at 2 years; we also held colouring competitions for 2-yearolds, off ering £50 shopping voucher prizes. At 2 years, we sent a postal questionnaire to non-respondents' family physicians (Health Professional Questionnaire [HPQ ]).
At 6, 12, and 24 months, participant questionnaires asked about maternal smoking behaviour and infants' respiratory problems. Information about hospital admissions (at all timepoints), feeding method (6 months and 12 months), and EuroQol (EQ-5D; 6 months) 16 were also collected, but are not reported here. The 24-month participant questionnaire (PQ2) included fi ve domains of the Ages and Stages Questionnaire 3rd edition (ASQ-3) 17 (communication, gross motor, fi ne motor, problem solving, and personalsocial development); with per mission, wording was slightly anglicised. Seven additional PQ2 items (six from the ASQ-3) investigated general and specifi c parental concerns about infant development. The HPQ, derived from a questionnaire used in a similar study, 18 was designed for completion with medical or health visitor records; items were consistent with PQ2, and hence ASQ-3, and aimed to measure children's disability and health (questionnaires can be requested from corresponding author). [19] [20] [21] Participants' Index of Multiple Deprivation (IMD) scores were attributed by linkage of postal codes with routine English Local Government data; 22 a higher score indicates more deprivation.
Outcomes
All of the outcomes were binary-ie, participants or infants were defi ned as either having the outcome or not.
PQ2 and HPQ responses were combined to derive the primary 2-year outcome, which was survival with no impairment. This was survival without either of two prespecifi ed developmental outcomes; developmental and behavioural problems or disability. Details of how PQ2 and HPQ items were mapped to these outcomes can be found online in the Statistical Analysis Plan. Because high rates of disability or developmental problems were not expected, combination of outcomes provided a clinically meaning ful measure of harm, with increased study power for detection of harm from NRT, and reduced problems arising from multiple testing. Appendix pp 5-6 provides separate results for each of the ASQ domains. For cases where both PQ2 and HPQ were returned, only PQ2 data were used. Details of how the absence, presence, or severity of impairment was determined from HPQ or PQ2 responses can be found online in the Statistical Analysis Plan. In brief, with the PQ2, infants were deemed to have survived with no impairment if scores, derived with standard methods for the fi ve ASQ-3 domains, were above accepted thresholds indicating normal development 17 and responses to other, non-domain, ASQ-3 items also indicated no problems. For children with HPQ returns only, this criterion was met if no responses indicated developmental problems. In cases for which scores and other responses indicated potential impairments, two further mutually-exclusive categories were allocated: defi nite and suspected develop mental impairment. Infants were classifi ed as having defi nite impairment when their ASQ-3 scores were at or below the published cut-point in any of the domains, or the HPQ responses indicated severe disability or developmental delay. Suspected impairment was used for cases in which one or more of the ASQ-3 scores fell within the questionnaire's borderline range, or if other responses from either the PQ2 or HPQ were judged by a clinical member of the research team to potentially indicate developmental impairment or disability. Deter mination of impairment category by this clinician was done masked to treatment allocation.
Infants were classed as having a respiratory problem when indicated by any item on either the PQ2 or HPQ. Similar to developmental problems, responses were combined to avoid multiple testing and to maximise power, but individual results are provided in appendix pp 7-8.
At all points, participants reported whether they had smoked in the last week, and if they had abstained from smoking since delivery, with allowance for smoking on up to fi ve occasions. 23 Prolonged abstinence from smoking since the quit date set during pregnancy was defi ned as validated abstinence at delivery, plus reported abstinence since delivery at every follow up.
Statistical analysis
Sample size for the trial was determined for the previously reported primary outcome of smoking cessation rate at delivery. 13 Within those participants available at follow-up, baseline maternal characteristics and birth outcomes were compared between trial groups; the same characteristics were also compared in those who had outcomes determined by PQ2, HPQ, or who were lost to follow-up at 2 years. Statistical analyses were done with Stata/SE version 11.2 (StataCorp LP, College Station, TX, USA).
NRT Placebo
Maternal characteristics at study enrolment; n=448 for NRT, n=452 for placebo*
Age ( Missing data (n) 35 33 Time from waking to fi rst cigarette (min) Separate multivariable analyses were done for presence or absence of every outcome, including the primary outcome (survival with no impairment), and for secondary outcomes (defi nite impairment, respiratory problems, and maternal smoking behaviour). For 2-year outcomes, treatment groups were compared on an intention-to-treat basis. Infant outcomes were only compared for pregnancies that were known to have resulted in live births. Pregnancies that ended in fetal death before birth (eg, miscarriage, stillbirth, or elective termination), and those for which the pregnancy outcome was unknown did not contribute to analyses, but postnatal infant deaths were included in the denominator for developmental outcomes. We did the primary analysis within singleton births, because nonindependent, multiple births might have worse birth outcomes than singletons. We then compared results with those obtained after multiple imputation to deal with missing values. Multiple imputation was done with mi commands in Stata, including complete baseline variables, smoking status at delivery, and treatment allocation in the imputation model (20 imputations). Treatment eff ects were estimated from imputed datasets with logistic regression adjusted for centre as the stratifi cation factor. We then did two further analyses; a complete case analysis including multiple births allowing for clustering, 24 and a further full population analysis with parent PQ2 questionnaires only.
In a prespecifi ed secondary analysis, we used logistic regression to explore the dose-response relation between self-reported adherence with nicotine patches 13 and, as a dependent variable, infants' survival without impairment. For this analysis, three categories were created: zero adherence (ie, allocated placebo patch or reported zero nicotine patches used) and, for participants reporting use of at least one nicotine patch, two categories representing above and below the median reported adherence of 10 nicotine patches (ie, 1-10 and 11-56 days adherence).
Smoking outcomes for the treatment groups at 6, 12, and 24 months were compared on an intention-to-treat basis, with non-respondents assumed to smoke. Logistic regression, adjusted for centre, provided odds ratios for the treatment eff ect, and a sensitivity analysis adjusted for baseline salivary cotinine, partner's smoking status, and age at fi nishing education was done. Finally, a sensitivity analysis investigated the eff ect on fi ndings of alternatives to the assumption that those with missing data were smokers. 25 The trial is registered with Controlled-Trials.com, number ISRCTN07249128.
Role of the funding source
The funders of this study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. SC, JT, SL, and TC had full access to the data in the study. SC and TC had the fi nal responsibility for the decision to submit for publication. Data are n (%), median (range), or mean (SD). PQ2=24-month participant questionnaire. HPQ=health professional questionnaire (also at 24 months). NRT=nicotine replacement therapy. *26 participants who provided both HPQ and PQ2 data were excluded from this analysis (n=12 for NRT, n=14 for placebo, all singleton pregnancies). †Includes participants who experienced fetal or infant death (n=18), whose pregnancy outcome was unknown (n=14), and those who withdrew, were lost to follow-up or did not return questionnaires at 24 months (n=118). Table 2 : Maternal and infant characteristics-comparison of participants and singleton infants for whom outcome data was and was not available at 2 years from 1036 pregnancies and completeness of infants' follow-up to 2 years (appendix p 2). Of singleton infants, 891 (88%) participants returned a PQ2 or HPQ; 445 (88%) of 503 infants given NRT and 446 (88%) of 507 infants given placebo. 26 (3%) of 990 participants were late returning their PQ2, and an HPQ had also been sent and returned; the PQ2 was our primary source of data and so these 26 HPQs were not analysed. Because of missing data, development outcomes were only attributable for 443 infants in the NRT group and 441 infants in the placebo group (including four postnatal infant deaths [two for NRT, two for placebo]) and respiratory outcomes for 444 infants in the NRT group and 444 infants in the placebo group. Of participants and singleton infants with 2-year outcome data, baseline characteristics and birth outcomes in the NRT and placebo groups were generally similar (table 1). These comparison groups at 2 years also had similar characteristics to those previously reported in the full trial cohort. 13 At 2 years, as seen at delivery, more births by caesarean occurred in the NRT group than in the placebo group (table 1). The proportion of mothers at 2 years who had had validated abstinence from smoking at delivery ( Table 2 shows a comparison of characteristics between participants who returned PQ2s, those for whom HPQs were completed, and those lost to follow-up. The mean IMD score was higher in those participants who were not followed up compared with that for PQ2 and for HPQ (table 2) , but most diff erences between the groups' baseline characteristics or birth outcomes were minor. Breastfeeding rates reported at 6 months were very similar in the two groups; 133 (40%) of 330 respondents in the NRT group reported breastfeeding exclusively immediately after childbirth compared with 126 (38%) of 333 in the placebo group, and by 6 months these rates had fallen to 14 (4%) participants for NRT and 10 (3%) for placebo. Table 3 shows infant developmental and respiratory outcomes by treatment groups for all those participants with known outcomes, including four postnatal deaths. Infants born to women receiving NRT were signifi cantly more likely to have survived with no impairment than those receiving placebo (table 3). In the ITT analysis with multiple imputation, the primary outcome was significantly more common in the NRT than in the placebo group (table 3) . Findings from complete case analyses of singleton pregnancies only and adjusted for clustering by twin pregnancies (table 3) , and from similar analyses of just PQ2 responses (excluding postnatal deaths) (appendix p 3), were very similar. For example, in the complete case analysis of PQ2 responses for singleton infants, the diff erence in primary outcomes between groups was comparable to that in the main analysis (OR 1·52, 95% CI 1·09-2·11, p=0·0124; appendix p 3). Analyses of individual ASQ-3 domains showed eff ects of similar size and direction, although only diff erences in the personal social domain reached statistical signifi cance. Findings from comparison of scores on individual domains were: fi ne motor skills (OR 1·30, 95% CI 0·82-2·08, p=0·27), gross motor skills (1·40, 0·87-2·22, ) at 2-year follow-up. †Because of missing data, developmental outcomes were not documented for seven participants (n=2 for HPQ in NRT group; n=1 for PQ2, n=4 for HPQ in placebo). Because of missing data, respiratory outcomes could not be determined for three participants (n=1 for HPQ in NRT group; n=1 for PQ2, n=1 for HPQ in placebo). ‡Score above borderline score in ASQ-3 for all domains, and no problems reported in additional sections of ASQ-3 (ie, any hearing, talking, understanding, neuromotor or vision problems). §ASQ-3 score equal to or below cutpoint in ≥1 domain, HPQ indicates severe disability and/or severe developmental delay. ¶ASQ-3 borderline score in ≥1 domain, but no scores equal to or below cut-point, and/or judged to have mild/moderate or possible impairment, disability or development delay from the additional questions on the PQ2 and/or HPQ including problems with hearing, speech, neuromotor, vision, behaviour, or feeding problems. ||Any report of respiratory symptoms, asthma diagnosis, asthma medications, or admissions to hospital for respiratory problems at 2-year follow-up; this denominator does not include postnatal infant deaths because it is not possible to attribute these infants with a respiratory outcome. **Because of missing data, denominators were diff erent for each outcome; total infants with known developmental outcomes (including postnatal infant deaths) was 888 (445 plus 443); total infants with known respiratory outcomes (excluding postnatal infant deaths) was 888 (444 plus 444). † †Infants from nine twin pregnancies returned a PQ2 or HPQ (n=6 for NRT, n=12 for placebo). ‡ ‡Because of missing data, denominators were diff erent for each outcome: total infants (including twins) with known developmental outcomes (including postnatal deaths) was 906 (451 plus 455); total infants (including twins) with known respiratory outcomes (excluding postnatal infant deaths) was 906 (450 plus 456). Table 3 : Infant development and respiratory outcomes at 2 years compared between treatment groups p=0·15), communication (1·21, 0·75-1·96, p=0·43), problem solving (1·34, 0·90-2·01, p=0·15), personal social (1·64, 1·08-2-48, p=0·0184; appendix p 5). The results showed a dose-response relation between use of NRT patches in pregnancy and infant outcomes at 2 years compared with infants born to participants who did not use nicotine patches, but we noted no diff erence in outcomes of infants born to women who reported using between one and 10 NRT patches (appendix p 9). However, those infants born to women who reported using between 11 and 56 NRT patches were more likely to have no impairments (OR [adjusted for partner smoking status] 1·72, 95% CI 1·22-2·57, p=0·004). Combined respiratory outcomes could be attributed for 888 of the singleton infants; 444 infants in the NRT group and 444 infants in the placebo group; of which 132 (30%) in the NRT group and 111 (25%) in the placebo group reported respiratory problems (table 3); further breakdown of respiratory outcomes is shown in appendix pp 7-8).
Results
Follow
For smoking outcomes, response rates at the three timepoints are shown in table 4, and are for all 1050 randomised women. Response rates were around 64% at 6 months, falling slightly to 58% at 2 years; these are lower than those for the developmental and respiratory outcomes as the smoking questions were only included in the participant questionnaires. After delivery, abstinence from smoking was low, and the relapse rate gradually increased (table 4) . Slightly more participants reported not smoking in the NRT group than placebo at each timepoint, but none were signifi cantly diff erent (table 4) . By 2 years after delivery, 15 (3%) participants allocated NRT and nine (2%) allocated placebo remained abstinent (table 4) ; the sensitivity analysis noted that varying the assumptions made that those with missing data were all smokers had almost no eff ect on this eff ect size.
Additional adverse events were not collected after delivery, but previously reported adverse pregnancy and birth outcomes were similar in the two groups.
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Discussion
At 2 years of age, infants born to women who had been allocated to receive NRT in pregnancy were more likely to have survived without developmental impairments than those in the placebo group, but no diff erences in the frequency of respiratory problems were noted (panel). NRT had only minor eff ects on smoking cessation, with very low prolonged abstinence rates 2 years after delivery. To our knowledge this is the fi rst time a trial has reported the eff ect of a smoking cessation intervention in pregnancy on infant outcomes beyond delivery, and also the fi rst time that maternal smoking rates within trial groups have been reported longer than 18 months after childbirth.
Using rigorous methods to maintain contact with participants, we achieved high outcome ascertainment rates, with low rates of withdrawal and missing data. In conjunction with staff doing the follow-up being masked to treatment allocation, this might account for the similar baseline characteristics of the two groups and the absence of systematic diff erences between those lost to follow-up and those included in analyses (tables 1, 2 Prolonged abstinence from smoking between quit date and 2 years after delivery ¶ 15 (3%) 9 (2%) 1·71 (0·74-3·94) 0·20 1·96 (0·82-4·70) 0·12
Data are n (%), unless otherwise indicated. NRT=nicotine replacement therapy. OR=odds ratio. PQ2=24-month participant questionnaire. *For the smoking outcomes, participants who did not provide data or were lost to follow-up are assumed to be smokers and included in the denominator. †Adjusted for centre only (as a stratifi cation factor). ‡Adjusted for centre, salivary cotinine concentration at baseline, partner's smoking status, and age at leaving full time education. §Self-reported prolonged abstinence since delivery in the table suggests the participant smoked less than fi ve times since baby was born. ¶Participant met criteria for prolonged abstinence at delivery (ie, positive primary outcome) plus self-reported smoking less than fi ve times since baby was born. ||Cessation information was collected at 1 year, but was not listed as an outcome in the protocol. **Smoking status was only ascertained in the PQ2. Table 4 : Maternal smoking outcomes at 6 months, 1 year, and 2 years after delivery status at delivery, and treatment allocation in the model and so should satisfactorily adjust for the minor diff erences in baseline characteristics of respondents such as mode of delivery; hence fi ndings from the analyses presented are likely to be internally valid. A medically qualifi ed researcher, masked to treatment allocation, manually checked all free-text responses on the outcome questionnaires and, if these generated uncertainty about either the presence or gravity of impairment, this was categorised as suspected, rather than defi nite or no impairment. This approach was also taken with respiratory item responses. The similar pattern of fi ndings across all pre-planned analyses, irrespective of data sources used, suggests consistent allocation of outcomes.
The ASQ-3, which was the basis of our parent-completed questionnaire, is a screening instrument designed to accurately identify children with develop mental problems and so avoid over-referrals and under-referrals for further assessment. 17 In a comparable setting, when compared with such subsequent assess ments, a similar earlier version of the ASQ had a sensitivity of 87·4% (specifi city 82·3%). 32 Although this sensitivity suggests that our outcome measure will have had good discrimination, some impaired infants will probably not have been detected and some non-impaired infants will have been wrongly labelled as impaired; face-to-face assessment would have been more accurate. However, the masking of respondents and outcome assessors make it unlikely that trial groups will have had diff erent rates of outcome misclassifi cation. Factors that were not measured, such as nutrition or environment, could have aff ected childhood development; however, this was a large randomised, blinded trial that was well-balanced for most characteristics that were collected. Developmental impairment is a fairly common outcome and, like all studies that use OR for an outcome that is not rare, our OR estimates might overestimate the risk ratio. Nevertheless, the observed diff erence in develop mental outcomes between trial groups is likely to be real and meaningful.
We assumed that all participants without smoking outcome data were smokers. Results of analyses investigating the eff ects of diff erent associations between smoking behaviour and being lost to follow up showed that alternative assumptions did not change the fi ndings; however, because smoking outcomes after delivery were not validated, actual prolonged quit rates could be even lower. Although we report data for maternal smoking status at 6 months, 1 year, and 2 years (table 4), data collected did not include cumulative number of cigarettes smoked, which would have been useful for assessment of whether or not NRT resulted in reduced smoking either during use or after its discontinuation. Nevertheless, because we note a signifi cant diff erence in validated quit rates 1 month after randomisation, which was reported in our previous paper (OR 2·10, 95% CI 1·49-2·97), 13 we do know that those in the NRT group had reduced their smoking more than those in the placebo group for at least 4 weeks during the second trimester-an important period in embryo development. Additionally, before 2 years of age, most infant exposure to environmental tobacco smoke (ETS) is domestic and attributable to parental smoking; 33 as a result, data for maternal smoking are likely to refl ect infants' exposure to ETS and the design of the study is such that any biases in reporting of smoking habits would aff ect both groups similarly. Unfortunately, after delivery, we collected no further biochemical measures of maternal smoking and no biomarkers of tobacco smoke exposure were obtained directly from the infants in the study, and so we cannot make any defi nitive conclusions about infants' exposure to ETS. Additionally, we acknowledge that participant recall or report of smoking might be inaccurate; however, there is no reason to believe that this will be diff erent between the groups. Also, we did not collect any data for alcohol intake during pregnancy, but because other baseline characteristics were similar we do not suspect that this would have been diff erent between the two groups.
We did not anticipate fi nding better outcomes in the infants in the NRT group; however, although less
Panel: Research in context
Systematic review When planning this trial, a published Cochrane review was consulted. 26 This systematic review established that at the outset of our trial (Feb 1, 2006) , only three randomised controlled trials [27] [28] [29] had investigated the use of nicotine replacement therapy (NRT) for smoking cessation in pregnancy, with no evidence from these that NRT was eff ective to help pregnant women stop smoking. Additionally, none of these trials had monitored maternal smoking rates after delivery or child outcomes such as respiratory symptoms or developmental impairment. More recently, two Cochrane reviews, including one authored by some of the SNAP team, have collated trials investigating pharmacological 14 and psychosocial cessation 30 interventions in pregnancy, and neither includes any studies that report infant outcomes beyond delivery. Evidence-based WHO guidance on smoking in pregnancy similarly showed no studies of smoking cessation during pregnancy that addressed infant outcomes, and recommended further research on the safety of pharmacotherapeutic cessation drugs.
31
Interpretation
To our knowledge, this is the fi rst time a trial has tested the eff ects of a smoking cessation intervention delivered in pregnancy on infant outcomes. We showed that NRT used for smoking cessation during pregnancy resulted in better infant developmental outcomes. These improved outcomes could have been caused by reduced maternal smoking during pregnancy, even though, overall, NRT was not considered eff ective for prolonged cessation. This fi nding should be further evaluated through reassessment of the infants of the SNAP trial in later childhood.
impairment was noted in children of mothers who reported greater than median adherence with nicotine patches, fi ndings from this analysis should be considered exploratory. The observed dose-response relation could suggest a real eff ect, attributable to NRT, but equally, alternative explanations might exist. For example, this analysis does not take into account the fact that people who adhere with treatments might diff er (eg, in lifestyle and health behaviours) from those who do not, and improved infant outcomes might have occurred because of diff erences other than the nicotine contained in the transdermal patches used in the trial. A direct benefi cial eff ect of nicotine on the developing fetus seems unlikely because animal studies suggest this might be toxic; 15, 34 however, animal studies might not be directly relevant to human beings and positive eff ects from nicotine cannot be ruled out. Benefi t might also have been mediated through reduced maternal smoking, although as the limitations noted suggest, this cannot be defi nitively proven from our data. Smoking in pregnancy has recently been reported to have a dose-response relation with conduct problems in off spring, an association that seems independent of either maternal characteristics or those of the child-rearing environment, including exposure to tobacco smoke after birth. 35 Most neurons are thought to develop in the fi rst two trimesters of pregnancy, with interconnections between these becoming organised between 24 weeks and term, however further maturation of these connections continues during the fi rst 2 years after birth and beyond, 36 and fetal cerebral growth continues into late pregnancy. 37 However, smaller brain volumes are associated with fetal exposure to maternal smoking 38 and it is feasible that normal brain developmental processes were disproportionately aff ected in foetuses in the placebo group. Diff erent mechanisms underpin fetal lung development, which might explain the absence of eff ect on respiratory outcomes. A similar, but smaller, placebo-controlled trial by Wisborg and colleagues 27 noted lower cotinine concentrations in mothers in the NRT group and signifi cantly higher birthweight in the NRT group. The trial also reported that NRT had no eff ect on abstinence throughout pregnancy. Superfi cially, these fi ndings could also seem to support the notion that NRT might reduce smoking enough to improve neonatal outcomes, even in the absence of an eff ect on sustained cessation. However, because diff erences in cotinine concentrations and smoking rates between trial groups in late pregnancy were both non-signifi cant, with much missing data for cotinine, and because no markers that are specifi c to tobacco smoke rather than NRT exposure were collected, we prefer not to hypothesise about potential reductions in fetal exposure to tobacco smoke in that study. Although such reductions remain a possibility, similar birthweight diff erences have not been consistently observed across other trials of NRT used for smoking cessation in pregnancy. 14 The hypothesis that the NRT eff ects were mediated through reduced smoking is consistent with evidence that smoking during pregnancy adversely aff ects human brain development. 39 Little evidence supports an alternative hypothesis that, when compared with smoking in pregnancy, nicotine has a directly benefi cial eff ect; however both hypotheses require further investigation because confi rmation of either has potentially major implications for the management of smoking in pregnancy.
